WoS İndeksli Yayınlar Koleksiyonu

Permanent URI for this collectionhttps://hdl.handle.net/20.500.14627/6

Browse

Filters

20262

Settings

Subject: search.filters.subject.Meta-analysis

Search Results

Now showing 1 - 2 of 2
  • Article
    Virtual Reality-Based Rehabilitation for Upper Extremity Recovery after Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    (Taylor & Francis Ltd, 2026) Ozturk, Basar
    Background: Stroke often results in upper extremity motor impairments, limiting functional independence. Conventional rehabilitation, while effective, faces challenges such as low engagement and high resource demand. Virtual reality (VR)-based rehabilitation may promote neuroplasticity through immersive and repetitive training. Objectives: To systematically evaluate randomized controlled trials (RCTs) assessing the effectiveness of VR-based rehabilitation on upper extremity motor recovery in stroke patients, and to explore the impact of system type, stroke chronicity, and intervention dosage. Methods: Following PRISMA 2020 guidelines (PROSPERO: CRD420251065021), a systematic search was conducted in PubMed, Scopus, Web of Science, and CENTRAL for RCTs published between 2010 and March 2025. Studies included adult stroke survivors receiving VR interventions targeting upper limb recovery. A random-effects meta-analysis calculated standardized mean differences (SMDs), and risk of bias was assessed using RoB 2.0. Results: Twenty-four RCTs (n = 1,627) were included. Meta-analysis of 21 studies showed a moderate effect favoring VR (SMD = 0.58; 95% CI: 0.38-0.78; p < 0.001; I-2 = 62%). Immersive VR, chronic stroke, and higher intervention doses (>600 min) showed stronger effects. Conclusions: VR-based rehabilitation significantly enhances upper extremity motor function post-stroke. Immersive systems and sufficient dosage yield optimal outcomes, supporting VR as a valuable adjunct to conventional therapy.
  • Article
    Efficacy and Safety of Deferiprone for Parkinson’s Disease: A Systematic Review and Meta-Analysis of Motor Function and Overall Disease Severity
    (Springer-Verlag Italia SRL, 2026) Ehab, Menna; Ibrahim, Ismail A.; Hekal, Rawan Gameel; Solah, Israa A.; Ezz-Alarab, Moaz; Elewa, Mandy; Zidat, Ayham R. A.
    Background The accumulation of iron in brain regions is one of the characteristics of Parkinson's disease (PD). Deferiprone (DFP) is an iron chelator that reduces iron overaccumulation in certain diseases. The efficacy and safety of DFP in the management of PD have been assessed; however, the results remain controversial. Method A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. A comprehensive search was conducted across five databases to identify all randomized clinical trials and observational studies. The primary outcomes included changes in motor function (MDS-UPDRS III) and overall disease severity (MDS-UPDRS total score). Additionally, the safety of DFP was assessed by analyzing adverse events. A network meta-analysis using a random-effects model was conducted. Results Four randomized clinical trials were identified. The studies included 567 patients with early-stage PD. The DFP doses across the included studies ranged from 3.75 to 15 mg/kg twice daily. None of the doses showed a significant Improvement in motor function (I2 = 0%), or in overall disease severity (I2 = 82.5%), compared with placebo in the network analysis. However, a non-significant improvement in motor function was observed at 7.5 mg/kg twice daily, whereas higher doses were associated with worsening clinical scores. Adverse events were generally mild, although there were some safety concerns at higher doses. Conclusion DFP can reduce accumulated iron across brain regions. However, current evidence does not support the use of DFP for the clinical and symptomatic management of PD within the assessed range of doses and treatment periods.